УКАЗАТЕЛЬ ЦИТИРУЕМОЙ ЛИТЕРАТУРЫ

1. Аксель Е.М. Статистика злокачественных новообразований женских половых органов. Клиническая онкогинекология. / под ред .Козаченко В.П. Москва «Медицина» 2005, стр.9-17.

2. Аксель Е.М.

3. Акуленко Л.В. Генетические аспекты рака органов женской репродуктивной системы. / Клиническая онкогинекология. Под. ред. Козаченко В.П. //Москва «Медицина» 2005, стр. 18-29.

4. Белушкина Н.Н. Особенности регуляции апоптоза опухолевых клеток/ Белушкина Н.Н.//Вестник Российской АМН.-2008.-№10.-с. 15-20

5. Винокуров В. Л. Рак яичников: закономерности метастазирования и выбор адекватного лечения больных/ Винокуров В. Л. //Санкт-Петербург.- Издательство «Фолиант».-2004.-336с.

6. Говорун В.М.,. // Биохимия Арчаков А.И, 2002, 67, ст. 1341-1359.

7. Жорданиа К.И. Опухоли яичников / Жорданиа К.И. Герштейн Е.С., Кушлинский Н.Е., Козаченко В.П., Блюменберг А.Г., Никогосян С.О.,

Губина О.В. // Клиническая онкогинекология. Под. ред. Козаченко В.П. Москва «Медицина» 2005, стр. 220-269.

8. Имянитов Е.Н. Молекулярная диагностика в онкологии/ Имянитов Е.Н. //Мол.Биол.-2008.-том 42№4.-772-785.

9. Карселадзе А.И. Морфология эпителиальных опухолей яичников. Автореф...дисс. докт.мед.наук. /Карселадзе А.И.// М.,1989.

10. Макаров О.В. Профилактика, диагностика, лечение рака яични- ков./Макаров О.В, Борисенко С.А. // Рос. мед. жури. 1996. - № 3. - С. 3640.

11. Макаров О.В. Иммунологические и гормональные нарушения у больных раком яичников. /Макаров О.В., Хашукоева А.З., Николаев Н.Н. //Труды V съезда акушеров-гинекологов РСФСР. Челябинск. - 1982 - стр. 204205.

12. Порханова Н.В. Рецидивы серозного рака яичников (факторы прогноза и диагностика)./Порханова Н.В. //Автореф. дисс. канд.мед.наук.М.,1999.

13. Прокопенко П.Г. Иммуноферментный анализ овариально-

метатстического антигена-8./Прокопенко П.Г.

14. Прокопенко П.Г. Перспективы диагностики и профилактики опухолей яичников./ Прокопенко П.Г. , Полторанина В.С., Петренко О.Ю., Терентьев А.А. // Успехи современного естествознания .-2011.-№9.-с. 53-62.

15. Стрижаков А.Н. Диагностическое и прогностическое значение определения сывороточных опухолевых маркеров в диффеенциальной диагностике новообразований яичников / Стрижаков А.Н ., Давыдов А.И., Мехдиев В.Э. // Материалы XXII международного конгресса с курсом эндоскопии «Новые технологии в диагностике и лечении гинекологических заболеваний»- М.- 2009.-С. 32.

16. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., Semmes O.J., Schellhammer P.F., Yasui Y., Feng Z., Wright G.L. Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. // Cancer Res., 2002; 62(13), p. 3609-3614.

17. Agarwal R., Kaye S.B. Expression profiling and individualisation of treatment for ovarian cancer. // Curr. Opin. Pharmacol. 2006; 6(4), p. 345349. Review.

18. Baranova A., Gowder S., Naouar S., King S., Schlauch K., Jarrar M., Ding Y., Cook B., Chandhoke V., Christensen A. Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor. // Int. J. Gynecol. Cancer. 2006; 16(6), p.1963-1972.

19. Bast R.C.Jr., Hennessy B., Mill G.B. The biology of ovarian cancer: new opportunities for translation//Nat. Rev.Cancer.-2009.-Vol.9, N.6.-P.415-443

20. Biran, H., Friedman, N., Neumann, L., Pras, M., and Shainkin-Kestenbaum, R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. // J. Clin. Pathol., 1986, 39, p. 794-797.

21. Brower S.T., Tartter P., Weiss S., Luderer A.A., Lehrer S. Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.

22. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.

23. Casl M.T., Coen D., Simic D. Serum amyloid A protein in the prediction of postburn complications and fatal outcome in patients with severe burns. // Eur. J. Clin. Chem. Clin. Biochem., 1996; 34(1), p. 31-35.

24. Casl M.T., Surina B., Glojnaric-Spasic I., Pape E., Jagarinec N., Kranjcevic S. Serum amyloid A protein in patients with acute myocardial infarction. // Ann. Clin. Biochem., 1995; 32 ( Pt 2), p.196-200.

25. Chan D.C., Chen C.J., Chu H.C., Chang W.K., Yu J.C., Chen Y.J., Wen L.L., Huang S.C., Ku C.H., Liu Y.C., Chen J.H. Evaluation of serum amyloid A as a biomarker for gastric cancer // Ann. Surg. Oncol. 2007; 14(1), p. 84-93.

26. Cho W.C., Yip T.T., Yip C., Yip V., Thulasiraman V., Ngan R.K., Yip T.T., Lau W.H., Au J.S., Law S.C., Cheng W.W., Ma V.W., Lim C.K. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. // Clin. Cancer Res., 2004; 10(1 Pt 1), p. 43-52.

27. Cramer D.W., Welch W.R.. Determinant of ovarian cancer risck II. Inferences Regading Pathogenesis. INCI, 1983, 71, 4, p.p. 717-721.

28. Cramer D.W., William R., Cossels B.S. et al. Mamps, menarche, menopause and ovarian cancer. Amer. J. Obstet. Gynecol., 1983, 147, p.p. 1-6.

29. Craven R.A., Totty N., Harnden P., Selby P.J., Banks R.E. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. // Am. J. Pathol., 2002;160(3), p. 815-822.

30. Crum CR, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9.

31. Diamandis E.P. Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma.

32. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. // Mol. Cell. Proteomics, 2004; 3(4), p. 367-378.

33. Diamandis E.P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? // Clin. Chem., 2003; 49(8), p.1272-1275.

34. Engwegen J.Y., Mehra N., Haanen J.B., Bonfrer J.M., Schellens J.H., Voest E.E., Beijnen J.H. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. // Lab. Invest. 2007; 87(2), p.161172.

35. Finch A, Shaw P, Rosen B. Clinical and pathologic findings: Salpingo- oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64

36. Gao W.M., Kuick R., Orchekowski R.P., Misek D.E., Qiu J., Greenberg A.K., Rom W.N., Brenner D.E., Omenn G.S., Haab B.B., Hanash S.M. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. // BMC Cancer, 2005; 5: 110.

37. Gericke B., Raila J., Sehouli J., Haebel S., Konsgen D., Mustea A., Schweigert F.J. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. // BMC Cancer, 2005; 5:133.

38. Glojnaric I., Casl M.T., Simic D., Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. // Clin. Chem. Lab. Med., 2001; 39(2), p.129-133.

39. Gutfeld, O., Prus, D., Ackerman, Z., Dishon, S., Linke, R.P., Levin, M., and Urieli-Shoval, S. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. // J Histochem.Cytochem., 2006, 54, p. 63-73.

40. Guyon, I., Weston, J., Bahnhill, S., Vapnik, V., Machine Learning 2002, 46, p. 389-422.

41. Hanahan W., Weinberg R.The hallmarks of cancer// Cell.-2000.-Vol.100.- P.57-70

42. Havrilesky L J, Sanders GD, Kulasingam S, et al. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity.

43. He R., Sang H., Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R.//Blood, 2003; 101(4), p. 15721581.

44. Huang S. Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev. 2013 May 3.

45. Jacobs I., Bast R.C. Jr. The CA 125 tumour-associated antigen: a review of the literature. // Hum. Reprod., 1989; 4(1), p. 1-12. Review.

46. Jacobs I.J., Menon U.. Progress and challenges in screening for early detection of ovarian cancer. // Mol. Cell. Proteomics, 2004. 3 № 4, p. 355366. Review.

47. Jacobs I.J., Rivera H., Oram D.H., Bast R.C. Jr. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.// Br. J. Obstet. Gynaecol., 1993; 100(12), p.1120-1124.

48. Jijon H.B., Madsen K.L., Walker J.W., Allard B., Jobin C. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. // Eur. J. Immunol. 2005; 35(3), p. 718-26.

49. Kaneti J., Winikoff Y., Zimlichman S., Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. // Urol. Res.; 1984, 12(5), p. 23941.

50. Katopodis N., Glantz M.J., Kim L., Dafni U., Wu J.K., Perides G. Lipid- associated sialoprotein in the cerebrospinal fluid: association with brain malignancies. // Cancer, 2001; 92(4), p. 856-862.

51. Kathleen R.Cho., Shih le-Ming. Ovarian cancer //Annu. Rev. Pathol.-2009.- Vol. 4.-P.287-313

52. Knudson A.G. Genetics and etiology of human cancer. Adv.Hum. Genetics, 1977, 8, p. 1-66.

53. Knudson A.G. Hereditary and cancer in man. Inst. Cancer Res. Sci. Rep., 1976-1977, N 22, p.p. 45-47.

54. Knudson AG. Hereditary cancers: from discovery to intervention. // J Natl Cancer Inst Monogr 1995; 17:5-7.

55. Kovacevic, A., Hammer, A., Sundl, M., Pfister, B., Hrzenjak, A., Ray, A., Ray, B.K., Sattler, W., and Malle, E.

56. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., Reddy S.T., Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. // Proc. Natl. Acad. Sci. U S A., 2003; 100(21), p.12343-12348.

57. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. // Proteomics, 2005; 5(17), p. 4589-96.

58. Kurman RT, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443

59. Larson M.A., Wei S.H., Weber A., Weber A.T., McDonald T.L. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. // Biochem. Biophys. Res. Commun., 2003; 301(4), p. 1030-1037.

60. Le L., Chi K., Tyldesley S., Flibotte S., Diamond D.L., Kuzyk M.A., Sadar M.D. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. // Clin. Chem., 2005; 51(4), p. 695-707.

61. Le Page C., Ouellet V., Madore J., Hudson T.J., Tonin P.N., Provencher D.M., Mes-Masson A.M. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. // Int J Cancer, 2006 Apr 1;118(7), p. 1750-1758.

62. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ 3rd, Lohr JG, Harris CC, Ding L, Wilson RK, Wheeler DA, Gibbs RA, Kucherlapati R, Lee C, Kharchenko PV, Park PJ; Landscape of somatic retrotransposition in human cancers.//Cancer Genome Atlas Research Network. Science. 2012 Aug 24;337(6097):967-71.

63. Lee H.Y., Kim M.K., Park K.S., Bae Y.H., Yun J., Park J.I., Kwak J.Y., Bae Y.S. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. // Biochem. Biophys. Res. Commun., 2005; 330(3), p. 989-998.

64. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Chen D.S., Yu C.Y., Wen C.L., Lu F.J., Chow L.P. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. // Proteomics, 2006; 6(9), p. 2865-2873.

65. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. // Clin. Chem. 2002; 48(8), p.1296-1304.

66. Lingeman C.H. Environmental factors in the etiology of human ovary: a review. Progr. Clin. Biol. Res.,1983, 117, p.p.365-379.

67. Liu D.H., Wang X.M., Zhang L.J., Dai S.W., Liu L.Y., Liu J.F., Wu S.S., Yang S.Y., Fu S., Xiao X.Y., He D.C. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. // Biomed. Environ. Sci. 2007; 20(1), p. 33-40.

68. Mao Y., Zhou X.B., Pi D.Y., Sun Y.X.. Constructing support vector machine ensembles for cancer classification based on proteomic profiling. // Genomics Proteomics Bioinformatics. 2005; 3(4), p. 238-241

69. Maslov AY, Ganapa-thi S, Westerhof M, Quispe-Tintaya W, White RR, Van Houten B, Reiling E, Dolle ME, van Steeg H, Hasty P, Hoeijmakers JH, Vijg J. DNA damage in normally and prematurely aged mice. Aging Cell. 2013 Jun;12(3):467-77. doi: 10.1111/acel.12071. Epub 2013 Apr 24.

70. Mayer J.M., Raraty M., Slavin J., Kemppainen E., Fitzpatrick J., Hietaranta A., Puolakkainen P., Beger H.G., Neoptolemos J.P. Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. // Br. J. Surg. 2002; 89(2), p. 163-171.

71. Miki Y. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 // Science. — 1994. — Vol. 266. — P. 66.

72. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., Yue L., Bray-Ward P., Ward D.C. Serum protein markers for early detection of ovarian cancer. // Proc. Natl. Acad. Sci. U S A, 2005; 102(21), p. 7677-7682.

73. Moshkovskii S.A., Serebryakova M.V., Kuteykin-Teplyakov K.B., Tikhonova O.V., Goufman E.I., Zgoda V.G., Taranets I.N., Makarov O.V., Archakov A.I. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. // Proteomics, 2005; 5(14), p. 3790-3797.

74. Mullan R.H., Bresnihan B., Golden-Mason L., Markham T., O'Hara R., FitzGerald O., Veale D.J., Fearon U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. // Arthritis Rheum., 2006; 54(1), p. 105-114.

75. Nakayama T., Sonoda S., Urano T., Yamada T., Okada M. Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases. // Clin. Chem., 1993; 39(2), p. 293-297.

76. Narod S.A., Feunten J., Lynch H.T., Watson P. et.al. Familial breast/ovarian cancer locus on chromosome 17q12-q23. Lancet., 1991, 338 (8759), p.p.82-

83.

77. Nedelkov D., Kiernan U.A., Niederkofler E.E., Tubbs K.A., Nelson R.W. Investigating diversity in human plasma proteins. // Proc. Natl. Acad. Sci. U S A., 2005 Aug 2;102(31), p.10852-10857.

78. Nozawa S., Aoki D., Yajima M., Tsukazaki K., Kobayashi T., Kimura E., Terashima Y., Inaba N., Takamizawa H., Negishi Y., et al. CA54/61 as a marker for epithelial ovarian cancer. // Cancer Res. 1992; 52(5), p.1205-1209.

79.O'Hara R., Murphy E.P., Whitehead A.S., FitzGerald O., Bresnihan B. Acute- phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res., 2000; 2(2), p. 142-144.

80. Partridge E, Kreimer AR, Greenlee RT, etl.Resultsfromfourroundsofovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113:775-782.

81. Petricoin E.3rd, Liotta L.A. Counterpoint: The vision for a new diagnostic paradigm. // Clin. Chem., 2003; 49(8), p. 1276-1278.

82. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. // Lancet, 2002; 359(9306), p. 572-577.

83. Petricoin E.F., Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. // Curr. Opin. Biotechnol., 2004;15(1):24-30.

84. Rai A.J., Zhang Z., Rosenzweig J., Shih IeM., Pham T., Fung E.T., Sokoll L.J., Chan D.W. Proteomic approaches to tumor marker discovery. // Arch Pathol Lab Med., 2002; 126(12), p.1518-1526.

85. Rau B., Steinbach G., Baumgart K., Gansauge F., Grunert A., Beger H.G. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. // Crit. Care Med., 2000; 28(3), p. 736742.

86. Rodland K.D. Mass spectrometry and biomarker development. // Dis. Markers. 2004; 20(3), p.129-130.

87. Rodland K.D. Proteomics and cancer diagnosis: the potential of mass spectrometry. // Clin. Biochem. 2004; 37(7), p. 579-583.

88. Rosenthal C.J., Franklin E.C., Frangione B., Greenspan J. Isolation and partial characterization of SAA-an amyloid-related protein from human serum. // J. Immunol., 1976; 116(5), p.1415-1418.

89.Siegel R, Ward E, Branty MD. Cancer statistics 2011. C A Cancer Clin. 2011;61:212-236

90.Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., de Bruijn H.W., van der Zee A.G., Woolas R.P., Jacobs I.J., Zhang Z., Bast R.C. Jr. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. // J. Clin. Oncol., 2004; 22(20), p. 4059-4066.

91.Skubitz A.P., Pambuccian S.E., Argenta P.A., Skubitz K.M. Differential gene expression identifies subgroups of ovarian carcinoma. // Transl. Res., 2006; 148(5), p. 223-248.

92.Stevens JB, Horne SD, Abdallah BY, Ye CJ, Heng HH. Chromosomal instability and transcriptome dynamics in cancer.//Cancer Metastasis Rev. 2013 Apr 18.

93. Tan A.C., Naiman D.Q., Xu L., Winslow R.L., Geman D. Simple decision rules for classifying human cancers from gene expression profiles. // Bioinformatics. 2005; 21(20):3896-3904.

94. Tavtigian S. V., Simard J., Rommens J. et al. The complete BRCA2 gene and mu-tations in chromosome 13q-linked kindreds // Nat. Genet. — 1996. — Vol. 12. — P. 333.

95. Thompson D., Easton D. Breast Cancer Linkage Consortium Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev., 2002, Vol. 11, N 4, p. 410-419.

96. Thompson D., Easton D. Variation in cancer risk, by mutation position, in

BRCA2 mutation carriers. Am. J.Hum. Genet., 2001, Vol.68, p. 410-419.

97. Tolson J., Bogumil R., Brunst E., Beck H., Elsner R., Humeny A., Kratzin H., Deeg M., Kuczyk M., Mueller G.A., Mueller C.A., Flad T. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. // Lab. Invest., 2004; 84(7), p. 845-856.

98. Toropygin I., Serebryakova M.V., Khrya-pova E.V., Mirgorodskaya O.A.// VI symposium "Chemistry of proteolytical enzymes", 2007. P. 54.

99. Ueland FR, DePriest P, Desimone C, et al. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol. Oncol.2005;99:400-403

100. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute- phase reactant. // Eur. J. Biochem., 1999; 265(2), p. 501-523. Review.

101. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. // Electrophoresis. 1997; 18(11), p. 2071-2077.

102. Vallon R., Freuler F., Desta-Tsedu N., Robeva A., Dawson J., Wenner P.., Engelhardt P., Boes L., Schnyder J., Tschopp C., Urfer R., Baumann G. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. // J. Immunol., 2001; 166(4), p. 2801-2807.

103. van Bennekum A.M., Wei S., Gamble M.V., Vogel S., Piantedosi R., Gottesman M., Episkopou V., Blaner W.S. Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. // J. Biol. Chem., 2001; 276(2), p.1107-1113.

104. Vapnik, V.N., Statistical Learning Theory, Springer-Verlag, New York 1998

105. Vijg J, Suh Y. Genome instability and aging. Annu Rev Physiol. 2013;75:645-68. doi: 10.1146/annurev-physiol-030212-183715.

106. Wamunyokoli F.W., Bonome T., Lee J.Y., Feltmate C.M., Welch W.R., Radonovich M., Pise-Masison C., Brady J., Hao K., Berkowitz R.S., Mok S., Birrer M.J. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. // Clin. Cancer Res., 2006; 12(3 Pt 1), p. 690-700.

107. Welsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast of breast and ovarian cancer. Hum. Molec. Genet., 2001, Vol.10, p. 705-713.

108. White C.N., Zhang Z., Chan D.W. Quality control for SELDI analysis. // Clin. Chem. Lab. Med., 2005; 43(2):125-126.

109. Wolters S, Schumacher B. Genome maintenance and transcription integrity in aging and disease. Front Genet. 2013;4:19.

110. Woolas R.P., Conaway M.R., Xu F., Jacobs I.J., Yu Y., Daly L., Davies A.P., O'Briant K., Berchuck A., Soper J.T., et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. // Gynecol. Oncol., 1995; 59(1), p 111-116.

111. Wooster R. Identification of the breast cancer susceptibility gene BRCA2 // Nature. — 1995. — Vol. 378. — P. 789—792.Аксель Е.М. Статистика злокачественных новообразований женских половых органов.// Клиническая онкогинекология. Под. ред. Козаченко В.П. //Москва «Медицина» 2005, стр. 9-17.

112. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. Proteomic applications for the early detection of cancer. // Nat. Rev. Cancer., 2003; 3(4), p. 267-75. Review.

113. Xiao Z., Prieto D., Conrads T.P., Veenstra T.D., Issaq H.J. Proteomic patterns: their potential for disease diagnosis. // Mol. Cell. Endocrinol., 2005; 230(1-2), p. 95-106. Review.

114. Xu F.J., Yu Y.H., Daly L., Anselmino L., Hass G.M., Berchuck A., Rodriguez G.C., Soper J.T., Clarke-Pearson D.L., Hollis D., et al. OVX1 as a marker for early stage endometrial carcinoma. // Cancer, 1994; 73(7), p.18551858.

115. Xu L., Tan A.C., Naiman D.Q., Geman D., Winslow R.L. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. // Bioinformatics, 2005; 21(20), p. 3905-3911.

116. Zhang X., Lu X., Shi Q., Xu X.Q., Leung H.C., Harris L.N., Iglehart J.D., Miron A., Liu J.S., Wong W.H. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. // BMC Bioinformatics. 2006; 7:197.

117. Zhang Z., Barnhill S.D., Zhang H., Xu F., Yu Y., Jacobs I., Woolas R.P., Berchuck A., Madyastha K.R., Bast R.C. Jr. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. // Gynecol. Oncol., 1999; 73(1), p. 56-61.

118. Zhang Z., Bast R.C. Jr., Yu Y., Li J., Sokoll L.J., Rai A.J., Rosenzweig J.M., Cameron B., Wang Y.Y., Meng X.Y., Berchuck A., Van Haaften-Day C., Hacker N.F., de Bruijn H.W., van der Zee A.G., Jacobs I.J., Fung E.T., Chan D.W. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. // Cancer Res., 2004; 64(16), p. 5882-5890.

119. Zhou G., Li H., DeCamp D., Chen S., Shu H., Gong Y., Flaig M., Gillespie J.W., Hu N., Taylor P.R., Emmert-Buck M.R., Liotta L.A., Petricoin E.F. 3rd, Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. // Mol. Cell. Proteomics, 2002; 1(2), p. 117-124.